Ladan Zand1, Vicente E Torres1, Timothy S Larson1, Bernard F King2, Sanjeev Sethi3, Eric J Bergstralh4, Andrea Angioi1, Fernando C Fervenza1. 1. Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA. 2. Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, USA. 3. Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA. 4. Department of Statistics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Abstract
BACKGROUND: To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. METHODS: Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. RESULTS: At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. CONCLUSIONS: Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers. CLINICAL TRIAL REGISTRATION NUMBER: NCT02511418.
BACKGROUND: To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. METHODS: Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. RESULTS: At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. CONCLUSIONS: Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers. CLINICAL TRIAL REGISTRATION NUMBER: NCT02511418.
Authors: Jarir Atthobari; Auke H Brantsma; Ron T Gansevoort; Sipke T Visser; Folkert W Asselbergs; Wiek H van Gilst; Paul E de Jong; Lolkje T W de Jong-van den Berg Journal: Nephrol Dial Transplant Date: 2006-05-23 Impact factor: 5.992
Authors: Frank H Mose; Thomas Larsen; Janni M Jensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen Journal: Scand J Clin Lab Invest Date: 2013-11-21 Impact factor: 1.713
Authors: Vicente E Torres; Jared J Grantham; Arlene B Chapman; Michal Mrug; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Diego Martin; Mark E Lockhart; William M Bennett; Marva Moxey-Mims; Kaleab Z Abebe; Yan Lin; James E Bost Journal: Clin J Am Soc Nephrol Date: 2010-11-18 Impact factor: 8.237
Authors: Melissa A Cadnapaphornchai; Diana M George; Kim McFann; Wei Wang; Berenice Gitomer; John D Strain; Robert W Schrier Journal: Clin J Am Soc Nephrol Date: 2014-04-10 Impact factor: 8.237
Authors: Vicente E Torres; Bernard F King; Arlene B Chapman; Marijn E Brummer; Kyongtae T Bae; James F Glockner; Kraisthith Arya; Dana Risk; Joel P Felmlee; Jared J Grantham; Lisa M Guay-Woodford; William M Bennett; Saulo Klahr; Catherine M Meyers; Xiaoling Zhang; Paul A Thompson; J Philip Miller Journal: Clin J Am Soc Nephrol Date: 2006-11-02 Impact factor: 8.237
Authors: Godela M Brosnahan; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Charity G Patterson; Kyongtae T Bae; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Ronald D Perrone; Theodore I Steinman; Vicente E Torres Journal: Curr Hypertens Rev Date: 2017
Authors: Sara S Jdiaa; Nedaa M Husainat; Razan Mansour; Mohamad A Kalot; Kerri McGreal; Fouad T Chebib; Ronald D Perrone; Alan Yu; Reem A Mustafa Journal: Kidney Int Rep Date: 2022-07-05